Indications
Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene. Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene.
Composition
- Active substance
- Lumacaftor, ivacaftor
- International name (INN)
- lumacaftor;ivacaftor
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Orkambi
- Active substance
- Lumacaftor, ivacaftor
- ATC code
- R07AX30
- Group
- Respiratory system
- Therapeutic area
- Cystic Fibrosis